Patents by Inventor Suh-Chin Wu
Suh-Chin Wu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230149533Abstract: The invention provides a SARS-CoV-2 mucosal vaccine composition, preparation, and use thereof. The SARS-CoV-2 mucosal vaccine composition comprises an antigen fusion protein which includes a SARS-CoV-2 antigen and a Type IIb heat-labile enterotoxin A subunit from Escherichia coli. Immunization with the antigen fusion protein elicits cellular and humoral immune responses, including systemic and mucosal immune responses, against SARS-CoV-2 in a subject, and thus protects the subject from viral infection.Type: ApplicationFiled: August 5, 2022Publication date: May 18, 2023Inventors: SUH CHIN WU, PIN-HAN CHOU, HE-CHIN HSIEH
-
Publication number: 20230058789Abstract: The present invention provides a SARS-CoV-2 chimeric VLP vaccine composition and an expressing vector and use thereof. The chimeric SARS-CoV-2 VLP comprises a VLP skeleton formed by the M1 protein and the M2 protein of influenza virus, and the chimeric spike protein of SARS-CoV-2, expressed on the surface of the VLP skeleton, the transmembrane domain of which is replaced by the transmembrane domain of a HA of influenza virus. The present invention also provides a recombinant vector expressing the chimeric SARS-CoV-2 VLP, and the use of the chimeric SARS-CoV-2 VLP for eliciting an immune response against SARS-CoV-2 variants.Type: ApplicationFiled: August 1, 2022Publication date: February 23, 2023Inventors: SUH CHIN WU, Wei Shuo Lin, Ting Hsuan Chen
-
Patent number: 10655137Abstract: Provided is an influenza mucosal vaccine composition and preparation and application thereof. This composition contains an antigen fusion protein which includes an influenza virus antigen and a Type IIb heat-labile enterotoxin A subunit from Escherichia coli. Immunization with this antigen fusion protein induces cellular and humoral immune responses, including systemic and mucosal immune responses, against a specific influenza virus in a subject, and therefore protects the subject from viral infection.Type: GrantFiled: August 3, 2018Date of Patent: May 19, 2020Assignee: NATIONAL TSING HUA UNIVERSITYInventors: Suh-Chin Wu, Shi-Wei Lin, Neos Tang, Ting-Hsung Chen
-
Patent number: 10501529Abstract: Provided herein are a mutant envelope protein of Zika virus and a nucleic acid molecule including a nucleotide sequence encoding the mutant envelope protein. The mutant envelope protein, which preferably has a threonine substitution at 105th position, or an asparagine substitution at 248th position and a threonine substitution at 250th position in an amino acid sequence of SEQ ID NO: 1, includes an N-glycan masking a fusion loop region of the mutant envelope protein of Zika virus. Also provided herein is a vaccine composition, including the mutant envelope protein or a recombinant virus including the nucleic acid molecule. Also provided herein is a method of preventing Zika virus infection and reducing antibody-dependent enhancement of dengue virus infection, including administering to a subject in need thereof an effective amount of a vaccine composition including the mutant envelope protein of Zika virus.Type: GrantFiled: July 17, 2018Date of Patent: December 10, 2019Assignee: NATIONAL TSING HUA UNIVERSITYInventors: Suh-Chin Wu, Shao-Ping Yang, Hsiao-Han Lin
-
Publication number: 20190248875Abstract: Provided herein are a mutant envelope protein of Zika virus and a nucleic acid molecule including a nucleotide sequence encoding the mutant envelope protein. The mutant envelope protein, which preferably has a threonine substitution at 105th position, or an asparagine substitution at 248th position and a threonine substitution at 250th position in an amino acid sequence of SEQ ID NO: 1, includes an N-glycan masking a fusion loop region of the mutant envelope protein of Zika virus. Also provided herein is a vaccine composition, including the mutant envelope protein or a recombinant virus including the nucleic acid molecule. Also provided herein is a method of preventing Zika virus infection and reducing antibody-dependent enhancement of dengue virus infection, including administering to a subject in need thereof an effective amount of a vaccine composition including the mutant envelope protein of Zika virus.Type: ApplicationFiled: July 17, 2018Publication date: August 15, 2019Inventors: Suh-Chin Wu, Shao-Ping Yang, Hsiao-Han Lin
-
Publication number: 20190225979Abstract: Provided is an influenza mucosal vaccine composition and preparation and application thereof. This composition contains an antigen fusion protein which includes an influenza virus antigen and a Type IIb heat-labile enterotoxin A subunit from Escherichia coli. Immunization with this antigen fusion protein induces cellular and humoral immune responses, including systemic and mucosal immune responses, against a specific influenza virus in a subject, and therefore protects the subject from viral infection.Type: ApplicationFiled: August 3, 2018Publication date: July 25, 2019Inventors: Suh-Chin Wu, Shi-Wei Lin, Neos Tang, Ting-Hsung Chen
-
Patent number: 10124054Abstract: Provided is a vaccine combination against multiple dengue virus serotypes and preparation thereof. The vaccine combination includes a first vaccine and a second vaccine, wherein the first vaccine includes a live-attenuated dengue virus and a live-attenuated chimeric dengue virus, and the second vaccine includes a plurality type of recombinant flagellin and envelope domain III fusion proteins, wherein an envelope domain III of each type of the recombinant flagellin and envelope domain III fusion proteins is derived from a different dengue virus serotype. Also provided is a method of preventing or treating viral infection by multiple dengue virus serotypes in a subject using the vaccine combination, including the steps of administering the first and then the second vaccines at a time interval of about 1-5 weeks.Type: GrantFiled: April 24, 2017Date of Patent: November 13, 2018Assignee: NATIONAL TSING HUA UNIVERSITYInventors: Suh-Chin Wu, Hsiao-Han Lin, Meng-Ju Tsai, Guan-Cheng Lin
-
Publication number: 20180133302Abstract: Provided is a vaccine combination against multiple dengue virus serotypes and preparation thereof. The vaccine combination includes a first vaccine and a second vaccine, wherein the first vaccine includes a live-attenuated dengue virus and a live-attenuated chimeric dengue virus, and the second vaccine includes a plurality type of recombinant flagellin and envelope domain III fusion proteins, wherein an envelope domain III of each type of the recombinant flagellin and envelope domain III fusion proteins is derived from a different dengue virus serotype. Also provided is a method of preventing or treating viral infection by multiple dengue virus serotypes in a subject using the vaccine combination, including the steps of administering the first and then the second vaccines at a time interval of about 1-5 weeks.Type: ApplicationFiled: April 24, 2017Publication date: May 17, 2018Inventors: SUH-CHIN WU, HSIAO-HAN LIN, MENG-JU TSAI, GUAN-CHENG LIN
-
Publication number: 20170342113Abstract: A recombinant H7 hemagglutinin derived from Chinese hamster ovary (CHO) cell. The recombinant H7 hemagglutinin includes a H7 hemagglutinin domain, a GCN4-pII trimerization motif, and a His-tag. The recombinant H7 hemagglutinin can be prepared as a protective vaccine composition with a pharmaceutically acceptable adjuvant. H7 hemagglutinin specific antibodies are elicited, and protection against H7N9 influenza virus is provided.Type: ApplicationFiled: September 2, 2016Publication date: November 30, 2017Inventors: Suh-Chin WU, Wen-Chun LIU, Ting-Hsuan CHEN
-
Patent number: 9688965Abstract: A recombinant neuraminidase based on amino acid sequence (SEQ ID NO: 1) of wild-type pH1N1-NA (A/Texas/05/2009) influenza virus is provided. The recombinant neuraminidase of the present invention has an ectodomain with an amino acid sequence identical to SEQ ID NO: 1 and replaced at specific positions 149, 344, 365 and 366 residue(s) with corresponding amino acids of other influenza viruses. The recombinant neuraminidase may incur cross-protective immunity and be used as universal influenza vaccine.Type: GrantFiled: April 13, 2015Date of Patent: June 27, 2017Assignee: National Tsing Hua UniversityInventors: Suh-Chin Wu, Wen-Chun Liu, Chia-Ying Lin
-
Patent number: 9644008Abstract: The invention provides a deglycosylated hemagglutinin, wherein the glycosylation site(s) on the stem region is removed. The deglycosylated hemagglutinin may induce neutralizing antibody against influenza virus, and cross-reactive protection against different virus. The invention also provides a method for manufacturing deglycosylated hemagglutinin, comprising aligning two or more hemagglutinin stem sequences of influenza virus, identifying the high conserved N-glycosylation site, and removing the high conserved N-glycosylation site. Thus, the N-glycosylation site cannot be glycosylated.Type: GrantFiled: March 7, 2014Date of Patent: May 9, 2017Assignee: National Tsing Hua UniversityInventors: Suh-Chin Wu, Wen-Chun Liu, Yun-Ju Huang
-
Publication number: 20160067328Abstract: A recombinant neuraminidase based on amino acid sequence (SEQ ID NO: 1) of wild-type pH1N1-NA (A/Texas/05/2009) influenza virus is provided. The recombinant neuraminidase of the present invention has an ectodomain with an amino acid sequence essentially identical to SEQ ID NO: 1 and replaced at specific positions 149, 344, 365 and 366 residue(s) with corresponding amino acids of other influenza viruses. The recombinant neuraminidase may incur cross-protective immunity and be used as universal influenza vaccine.Type: ApplicationFiled: April 13, 2015Publication date: March 10, 2016Inventors: Suh-Chin WU, Wen-Chun LIU, Chia-Ying LIN
-
Patent number: 9150620Abstract: The present invention relates to a recombinant DNA molecule encoding a mutated hemagglutinin protein, wherein the mutated hemagglutinin protein consists of the amino acid sequence of SEQ ID NO: 2 with one or more mutations at amino acid residue selecting from the group consisting of residue 83, 127, 138 and the combination thereof. The present invention also relates to a composition comprising the recombinant DNA molecule as described above and a pharmaceutically or veterinarily acceptable carrier, excipient, adjuvant, or vehicle. The present invention further relates to a kit for prime-boost vaccination, comprising at least a composition comprising a recombinant DNA molecule as described above and at least a composition for the boost-vaccination comprising a recombinant hemagglutiinin protein or a virus-like particle, wherein the recombinant hemagglutiinin protein is the corresponding hemagglutiinin protein encoded by the recombinant DNA molecule.Type: GrantFiled: March 19, 2014Date of Patent: October 6, 2015Assignee: NATIONAL TSING HUA UNIVERSITYInventors: Suh-Chin Wu, Shih-Chang Lin
-
Publication number: 20150183833Abstract: The invention provides a deglycosylated hemagglutinin, wherein the glycosylation site(s) on the stem region is removed. The deglycosylated hemagglutinin may induce neutralizing antibody against influenza virus, and cross-reactive protection against different virus. The invention also provides a method for manufacturing deglycosylated hemagglutinin, comprising aligning two or more hemagglutinin stem sequences of influenza virus, identifying the high conserved N-glycosylation site, and removing the high conserved N-glycosylation site. Thus, the N-glycosylation site cannot be glycosyalted.Type: ApplicationFiled: March 7, 2014Publication date: July 2, 2015Applicant: National Tsing Hua UniversityInventors: Suh-Chin WU, Wen-Chun LIU, Yun-Ju HUANG
-
Patent number: 8889147Abstract: A DNA vaccine comprising hyperglycosylated mutant HA gene, which is derived from avian influenza virus, is provided. A DNA vaccine composition comprising: (a) the DNA vaccine; and (b) a booster is also provided. An influenza virus-like particle comprising adjuvant-fused M2 protein is further provided. A method for eliciting an immune response against a plurality of avian influenza virus subtypes in a subject, comprising delivering the DNA vaccine or the DNA vaccine composition to tissue of the subject is also provided.Type: GrantFiled: April 18, 2012Date of Patent: November 18, 2014Assignee: National Tsing Hua UniversityInventors: Suh-Chin Wu, Shih-Chang Lin
-
Publication number: 20140221628Abstract: A DNA vaccine comprising hyperglycosylated mutant HA gene, which is derived from avian influenza virus, is provided. A DNA vaccine composition comprising: (a) the DNA vaccine; and (b) a booster is also provided. An influenza virus-like particle comprising adjuvant-fused M2 protein is further provided.Type: ApplicationFiled: April 8, 2014Publication date: August 7, 2014Applicant: NATIONAL TSING HUA UNIVERSITYInventors: Suh-Chin Wu, Wen-Chun Liu, Hung-Ju Wei
-
Publication number: 20140193448Abstract: The present invention relates to a recombinant DNA molecule encoding a mutated hemagglutinin protein, wherein the mutated hemagglutinin protein consists of the amino acid sequence of SEQ ID NO: 2 with one or more mutations at amino acid residue selecting from the group consisting of residue 83, 127, 138 and the combination thereof. The present invention also relates to a composition comprising the recombinant DNA molecule as described above and a pharmaceutically or veterinarily acceptable carrier, excipient, adjuvant, or vehicle. The present invention further relates to a kit for prime-boost vaccination, comprising at least a composition comprising a recombinant DNA molecule as described above and at least a composition for the boost-vaccination comprising a recombinant hemagglutiinin protein or a virus-like particle, wherein the recombinant hemagglutiinin protein is the corresponding hemagglutiinin protein encoded by the recombinant DNA molecule.Type: ApplicationFiled: March 19, 2014Publication date: July 10, 2014Applicant: NATIONAL TSING HUA UNIVERSITYInventors: Suh-Chin Wu, Shih-Chang Lin
-
Publication number: 20130280296Abstract: A DNA vaccine comprising hyperglycosylated mutant HA gene, which is derived from avian influenza virus, is provided. A DNA vaccine composition comprising: (a) the DNA vaccine; and (b) a booster is also provided. An influenza virus-like particle comprising adjuvant-fused M2 protein is further provided.Type: ApplicationFiled: April 18, 2012Publication date: October 24, 2013Applicant: NATIONAL TSING HUA UNIVERSITYInventors: Suh-Chin Wu, Shih-Chang Lin
-
Publication number: 20120269853Abstract: The present invention relates to an attenuated dengue virus vaccine. In present invention, target mutagenesis at Glu345Lys was constructed in two infectious cDNA clones of a recombinant version of wild type virus DEN-4 2A and its derived 3? NCR deletion mutant vaccine candidate virus DEN-4 2A?30. Using PCR-mediated site-directed mutagenesis method, the infectious cDNA clone-derived Glu345-Lys mutants of DEN-4 2A and DEN-4 2A?30 were passaged in Vero cells and MRC-5 cells for five consecutive times. The results shows that single point mutation E-Glu345Lys of DEN-4 2A and DEN-4 2A?30 were found stably existed when passaged in MRC-5 cells, which means mutagenesis at Glu345Lys of DEN-4 2A and DEN-4 2A?30 are both suitable to be probagated in MRC-5 cell for producing virulence attenuated dengue virus vaccine.Type: ApplicationFiled: April 20, 2011Publication date: October 25, 2012Applicant: NATIONAL TSING HUA UNIVERSITYInventors: Suh-Chin Wu, Hsiang-Chi Lee, Hung-Ju Hsiao, Hsiao-Han Lin
-
Publication number: 20100197012Abstract: Biological materials are applied to a CHO cell or the like for enhancing production of a species of protein. The biological materials includes an expression vector and a silencing vector, the expression vector including a dhfr gene of a species of mammal and a gene encoding the species of protein, the silencing vector including a DNA fragment for inducing a RNA interference in the CHO cell to reduce expressions of both exogenous dhfr gene and endogenous dhfr gene after the biological material is applied to the CHO cell, and the CHO cell is thus not limited to dhfr gene deficient type. The DNA fragment consists of nucleotides characterizing a segment of a dhfr gene of the CHO cell and a segment of a dhfr gene of the species of mammal.Type: ApplicationFiled: April 15, 2010Publication date: August 5, 2010Applicant: NATIONAL TSING HUA UNIVERSITYInventors: Suh-Chin Wu, Willy W.L. Hong